{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acetate&page=6",
    "query": {
      "intervention": "acetate",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 1448,
    "total_pages": 145,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acetate&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=acetate&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T02:30:45.081Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05626478",
      "title": "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Corneal Edema",
        "Corneal Defect",
        "Anterior Chamber Inflammation",
        "Ocular Pain",
        "Corneal Staining",
        "Visual Outcome",
        "CME - Cystoid Macular Edema"
      ],
      "interventions": [
        {
          "name": "Dextenza 0.4Mg Ophthalmic Insert",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Acetate 1% Oph Susp",
          "type": "DRUG"
        },
        {
          "name": "Prolensa 0.07% Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicole Fram M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-06-01",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05626478"
    },
    {
      "nct_id": "NCT07723248",
      "title": "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Rinzimetostat",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ORIC Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 600,
      "start_date": "2026-08-03",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 11,
      "location_summary": "Coral Springs, Florida • Jeffersonville, Indiana • Holland, Michigan + 8 more",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        },
        {
          "city": "Holland",
          "state": "Michigan"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07723248"
    },
    {
      "nct_id": "NCT01994590",
      "title": "Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Dovitinib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2014-05-19",
      "completion_date": "2017-06-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01994590"
    },
    {
      "nct_id": "NCT05467397",
      "title": "Feasibility of [11C]Acetate-PET in LAM and TSC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphangioleiomyomatosis",
        "Tuberous Sclerosis Complex"
      ],
      "interventions": [
        {
          "name": "[11C]acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2021-08-30",
      "completion_date": "2026-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05467397"
    },
    {
      "nct_id": "NCT02069808",
      "title": "Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Egg Donation"
      ],
      "interventions": [
        {
          "name": "Follistim",
          "type": "DRUG"
        },
        {
          "name": "Ganirelix",
          "type": "DRUG"
        },
        {
          "name": "Menotropins",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide",
          "type": "DRUG"
        },
        {
          "name": "Transvaginal ultrasound guided needle aspiration of oocytes",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Michigan Reproductive Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "28 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 28 Years · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2014-04",
      "completion_date": "2017-03-08",
      "has_results": false,
      "last_update_posted_date": "2018-03-23",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 1,
      "location_summary": "Bloomfield Hills, Michigan",
      "locations": [
        {
          "city": "Bloomfield Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02069808"
    },
    {
      "nct_id": "NCT03488225",
      "title": "Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia in Remission",
        "B Acute Lymphoblastic Leukemia",
        "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-03-28",
      "completion_date": "2020-04-02",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03488225"
    },
    {
      "nct_id": "NCT00107107",
      "title": "Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "pramlintide acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2002-11",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2015-09-23",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 25,
      "location_summary": "Tempe, Arizona • Concord, California • Fresno, California + 22 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00107107"
    },
    {
      "nct_id": "NCT01120236",
      "title": "Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Recurrent Prostate Carcinoma",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        },
        {
          "name": "Cixutumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Goserelin Acetate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 211,
      "start_date": "2010-12",
      "completion_date": "2017-08-23",
      "has_results": true,
      "last_update_posted_date": "2018-02-26",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 169,
      "location_summary": "Fairbanks, Alaska • Little Rock, Arkansas • Rogers, Arkansas + 117 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01120236"
    },
    {
      "nct_id": "NCT02912364",
      "title": "Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Eslicarbazepine",
          "type": "DRUG"
        },
        {
          "name": "Carbamazepine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 46,
      "start_date": "2016-07",
      "completion_date": "2018-04-20",
      "has_results": true,
      "last_update_posted_date": "2019-06-04",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912364"
    },
    {
      "nct_id": "NCT03103087",
      "title": "LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heavy Menstrual Bleeding",
        "Uterine Fibroid"
      ],
      "interventions": [
        {
          "name": "Relugolix",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate",
          "type": "DRUG"
        },
        {
          "name": "Relugolix placebo",
          "type": "DRUG"
        },
        {
          "name": "Estradiol/norethindrone acetate placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Myovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 382,
      "start_date": "2017-06-14",
      "completion_date": "2020-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-20",
      "last_synced_at": "2026-10-31T02:30:45.081Z",
      "location_count": 89,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03103087"
    }
  ]
}